- Home
- AVBP vs LENZ Comparison
AVBP vs LENZ Comparison
Compare AVBP & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVBP
- LENZ
- Stock Information
- Founded
- AVBP 2021
- LENZ 2019
- Country
- AVBP United States
- LENZ United States
- Employees
- AVBP N/A
- LENZ N/A
- Industry
- AVBP
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- AVBP
- LENZ Health Care
- Exchange
- AVBP NYSE
- LENZ Nasdaq
- Market Cap
- AVBP 948.5M
- LENZ 886.2M
- IPO Year
- AVBP 2024
- LENZ 2021
- Fundamental
- Price
- AVBP $27.45
- LENZ $35.50
- Analyst Decision
- AVBP Strong Buy
- LENZ Strong Buy
- Analyst Count
- AVBP 5
- LENZ 6
- Target Price
- AVBP $36.80
- LENZ $35.40
- AVG Volume (30 Days)
- AVBP 146.0K
- LENZ 158.6K
- Earning Date
- AVBP 11-13-2024
- LENZ 11-06-2024
- Dividend Yield
- AVBP N/A
- LENZ N/A
- EPS Growth
- AVBP N/A
- LENZ N/A
- EPS
- AVBP N/A
- LENZ N/A
- Revenue
- AVBP N/A
- LENZ N/A
- Revenue This Year
- AVBP N/A
- LENZ N/A
- Revenue Next Year
- AVBP N/A
- LENZ N/A
- P/E Ratio
- AVBP N/A
- LENZ N/A
- Revenue Growth
- AVBP N/A
- LENZ N/A
- 52 Week Low
- AVBP $14.35
- LENZ $2.12
- 52 Week High
- AVBP $36.37
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- AVBP 41.86
- LENZ 65.22
- Support Level
- AVBP $33.17
- LENZ $31.59
- Resistance Level
- AVBP $28.82
- LENZ $35.40
- Average True Range (ATR)
- AVBP 1.99
- LENZ 2.79
- MACD
- AVBP -0.81
- LENZ -0.06
- Stochastic Oscillator
- AVBP 16.79
- LENZ 68.41
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.